File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1365-2125.2011.04063.x
- Scopus: eid_2-s2.0-83155176037
- PMID: 21762204
- WOS: WOS:000297790200016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Unlicensed use of metformin in children and adolescents in the UK
Title | Unlicensed use of metformin in children and adolescents in the UK |
---|---|
Authors | |
Keywords | Adolescents Children Diabetes Metformin Obesity Polycystic ovary syndrome |
Issue Date | 2012 |
Publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP |
Citation | British Journal Of Clinical Pharmacology, 2012, v. 73 n. 1, p. 135-139 How to Cite? |
Abstract | AIM: Metformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0-18 years in the UK. METHODS: Population-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010. RESULTS: A total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P= 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n= 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n= 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only. CONCLUSIONS: Prescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. |
Persistent Identifier | http://hdl.handle.net/10722/171437 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 1.046 |
PubMed Central ID | |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hsia, Y | en_US |
dc.contributor.author | Dawoud, D | en_US |
dc.contributor.author | Sutcliffe, AG | en_US |
dc.contributor.author | Viner, RM | en_US |
dc.contributor.author | Kinra, S | en_US |
dc.contributor.author | Wong, ICK | en_US |
dc.date.accessioned | 2012-10-30T06:14:12Z | - |
dc.date.available | 2012-10-30T06:14:12Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | British Journal Of Clinical Pharmacology, 2012, v. 73 n. 1, p. 135-139 | en_US |
dc.identifier.issn | 0306-5251 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171437 | - |
dc.description.abstract | AIM: Metformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0-18 years in the UK. METHODS: Population-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010. RESULTS: A total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P= 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n= 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n= 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only. CONCLUSIONS: Prescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. | en_US |
dc.language | eng | en_US |
dc.publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP | en_US |
dc.relation.ispartof | British Journal of Clinical Pharmacology | en_US |
dc.subject | Adolescents | - |
dc.subject | Children | - |
dc.subject | Diabetes | - |
dc.subject | Metformin | - |
dc.subject | Obesity | - |
dc.subject | Polycystic ovary syndrome | - |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Cohort Studies | en_US |
dc.subject.mesh | Diabetes Mellitus - Drug Therapy | en_US |
dc.subject.mesh | Drug Prescriptions - Statistics & Numerical Data | en_US |
dc.subject.mesh | Drug Utilization - Legislation & Jurisprudence - Trends | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Great Britain | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypoglycemic Agents - Therapeutic Use | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Legislation, Drug | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Metformin - Therapeutic Use | en_US |
dc.subject.mesh | Obesity - Drug Therapy | en_US |
dc.subject.mesh | Off-Label Use | en_US |
dc.subject.mesh | Physician's Practice Patterns - Statistics & Numerical Data - Trends | en_US |
dc.subject.mesh | Polycystic Ovary Syndrome - Drug Therapy | en_US |
dc.subject.mesh | Retrospective Studies | en_US |
dc.title | Unlicensed use of metformin in children and adolescents in the UK | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wong, ICK:wongick@hku.hk | en_US |
dc.identifier.authority | Wong, ICK=rp01480 | en_US |
dc.description.nature | link_to_OA_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1365-2125.2011.04063.x | en_US |
dc.identifier.pmid | 21762204 | - |
dc.identifier.pmcid | PMC3248263 | - |
dc.identifier.scopus | eid_2-s2.0-83155176037 | en_US |
dc.identifier.hkuros | 207213 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-83155176037&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 73 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 135 | en_US |
dc.identifier.epage | 139 | en_US |
dc.identifier.isi | WOS:000297790200016 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Hsia, Y=35068032100 | en_US |
dc.identifier.scopusauthorid | Dawoud, D=26639217600 | en_US |
dc.identifier.scopusauthorid | Sutcliffe, AG=7005644774 | en_US |
dc.identifier.scopusauthorid | Viner, RM=7005899067 | en_US |
dc.identifier.scopusauthorid | Kinra, S=6603836017 | en_US |
dc.identifier.scopusauthorid | Wong, ICK=7102513915 | en_US |
dc.customcontrol.immutable | csl 130312 | - |
dc.identifier.issnl | 0306-5251 | - |